Pfizer appears to be in the driver’s seat in the global Covid-19 vaccine market. Their jab has demonstrated high efficacy and their sales have jumped up to $1.4 Billion.
J&J reported $100 million in first-quarter sales of its Covid-19 shot.
However, it is currently on hold in America while federal health regulators investigate a rare blood-clotting issue.
Is the US about to turn its back on the drugmaker?
Timestamps
– PFE 02:25
– JNJ 03:15
